InvestorsHub Logo
Followers 37
Posts 2960
Boards Moderated 0
Alias Born 01/14/2003

Re: couldbebetter post# 239171

Wednesday, 01/08/2020 10:09:07 AM

Wednesday, January 08, 2020 10:09:07 AM

Post# of 425915
About icosabutate
Icosabutate is a patent protected, new chemical entity, and a structurally enhanced fatty acid developed as a synthetic modification of the omega-3 fatty acid eicosapentaenoic acid (EPA). Compared to currently available prescription omega-3 fatty acid formulations which are usually given as 4 grams a day to achieve clinical efficacy, icosabutate is designed to provide superior triglyceride-lowering at a much lower dose (600 mg) with a convenient once daily oral dosing with or without meals.

https://industries.basf.com/en/Omega-3/News-Events/News-Release/2015/Phase-2a-Clinical-Study-of-Icosabutate-in-Patients-with-Severe-Hypertriglyceridemia.html

It's the ratio, baby ... the EPA/AA ratio!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News